Welcome to our dedicated page for Allogene Therapeutics news (Ticker: ALLO), a resource for investors and traders seeking the latest updates and insights on Allogene Therapeutics stock.
Allogene Therapeutics develops allogeneic chimeric antigen receptor T cell, or AlloCAR T, product candidates for cancer and autoimmune disease. The clinical-stage biotechnology company focuses on off-the-shelf CAR T approaches, including cemacabtagene ansegedleucel, or cema-cel, in large B-cell lymphoma and ALLO-329, a dual CD19/CD70 CAR T candidate for autoimmune diseases.
Recurring news covers clinical and regulatory updates for Allogene's studies, scientific presentations and publications, platform technologies such as Dagger®, and data related to MRD-guided treatment approaches. Company updates also include quarterly financial results, business updates, shareholder matters, and common stock financing activity tied to research, development, clinical trials, and corporate operations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.